There Are Many Types of Obesity, Says This GLP-1 ExpertThere Are Many Types of Obesity, Says This GLP-1 Expert
A renowned physician-scientist says treatment is not one-size-fits-all. A renowned physician-scientist says treatment is not one-size-fits-all.
GLP-1 Drugs and Liver Complications; Tracking Endoscopists’ Eyes; Peppermint for IBSGLP-1 Drugs and Liver Complications; Tracking Endoscopists’ Eyes; Peppermint for IBS
(MedPage Today) — GLP-1 receptor agonists and SGLT2 inhibitors were associated with lower risks for liver-related events and hepatocellular carcinoma (HCC) in type 2 diabetes patients compared with other glucose-lowering therapies, a systematic… (MedPage Today) — GLP-1 receptor agonists and SGLT2 inhibitors were associated with lower risks for liver-related events and hepatocellular carcinoma (HCC) Read More
Blood biomarker points to increased risk of brain metastasis in patients with inflammatory breast cancerBlood biomarker points to increased risk of brain metastasis in patients with inflammatory breast cancer
Researchers at The University of Texas MD Anderson Cancer Center have identified a targetable driver of brain metastases in patients with aggressive inflammatory breast cancer. The study uncovers a novel role for soluble E-cadherin (sEcad) in promoting tumor invasion while resisting cancer cell death and triggering brain inflammation via the CXCR2 signaling pathway.
Minimally invasive test offers new insights into breast cancer spread and immune responseMinimally invasive test offers new insights into breast cancer spread and immune response
New research led by King’s College London suggests that a simple test already used in clinics could provide valuable additional insights into how the body’s immune system responds to cancer, without requiring any extra procedures for patients.
‘Night Owls’ and Heart Risks; AI Grades Med School Exams; GLP-1 Drug Patients Sue’Night Owls’ and Heart Risks; AI Grades Med School Exams; GLP-1 Drug Patients Sue
(MedPage Today) — Note that some links may require registration or subscription. “Night owls” may be at higher cardiovascular disease, but it mostly comes down to their overall health behaviors, according to a U.K. Biobank cohort study. (Journal… (MedPage Today) — Note that some links may require registration or subscription. “Night owls” may be Read More
Palbociclib as adjunct maintenance therapy prolongs progression-free survival in some types of metastatic breast cancerPalbociclib as adjunct maintenance therapy prolongs progression-free survival in some types of metastatic breast cancer
1. This randomized controlled trial found that, in patients with hormone-receptor-positive, HER2-positive metastatic breast cancer, the addition of palbociclib to standard therapy extended progression-free survival by more than one year. 2. Adverse events, most commonly neutropenia, were more frequent with palbociclib, though no deaths were determined to be related to the treatment. Evidence Rating Level:
The post Palbociclib as adjunct maintenance therapy prolongs progression-free survival in some types of metastatic breast cancer first appeared on 2 Minute Medicine. Source: 2 Minute Medicine
Research improves risk assessment for hereditary breast cancerResearch improves risk assessment for hereditary breast cancer
Researchers at LUMC have made a breakthrough in understanding PALB2 mutations, an important cause of hereditary breast cancer. By identifying which mutations affect the function of PALB2, doctors can now assess much more accurately which mutations are linked to an increased risk of breast cancer.
Sacituzumab govitecan plus pembrolizumab improves survival in advanced triple-negative breast cancerSacituzumab govitecan plus pembrolizumab improves survival in advanced triple-negative breast cancer
1. Among patients with previously untreated programmed death-ligand 1 positive, triple-negative breast cancer, first-line sacituzumab govitecan plus pembrolizumab significantly prolonged progression-free survival compared to chemotherapy plus pembrolizumab. 2. The sacituzumab combination was also associated with longer response duration and fewer treatment discontinuations due to adverse events, despite similar rates of high-grade toxicities. Evidence Rating Level:
The post Sacituzumab govitecan plus pembrolizumab improves survival in advanced triple-negative breast cancer first appeared on 2 Minute Medicine. Source: 2 Minute Medicine
Dual GIP/GLP-1 Drug Linked to Reduced Diabetic Retinopathy IncidenceDual GIP/GLP-1 Drug Linked to Reduced Diabetic Retinopathy Incidence
(MedPage Today) — Use of tirzepatide (Mounjaro, Zepbound) was tied to a reduced incidence of new or progressive diabetic retinopathy and fewer complications in patients with diabetes and overweight/obesity, a retrospective study suggested. In… (MedPage Today) — Use of tirzepatide (Mounjaro, Zepbound) was tied to a reduced incidence of new or progressive diabetic retinopathy Read More
Study raises red flags over long-term effectiveness of popular weight loss drugs like OzempicStudy raises red flags over long-term effectiveness of popular weight loss drugs like Ozempic
Ozempic, Mounjaro, and Zepbound can drive impressive weight loss, but stopping them is often followed by rapid weight regain. Researchers found that people regain weight faster after quitting these drugs than after diet and exercise alone. Improvements in heart health and diabetes risk also tend to reverse within a few years. The results suggest long-term Read More